SNTS Share Price

Open 31.99 Change Price %
High 32.04 1 Day -0.01 -0.03
Low 31.96 1 Week 0.00 0.00
Close 31.96 1 Month 0.00 0.00
Volume 5682564 1 Year 0.00 0.00
52 Week High 0.45
52 Week Low 0.15
SNTS Important Levels
Resistance 2 32.03
Resistance 1 32.00
Pivot 31.99
Support 1 31.92
Support 2 31.89
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Santarus, Inc. (NASDAQ: SNTS)

SNTS Technical Analysis 5
As on 31st Dec 2013 SNTS Share Price closed @ 31.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 22.17 & Strong Buy for SHORT-TERM with Stoploss of 29.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
SNTS Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SNTS Other Details
Segment EQ
Market Capital 577287168.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SNTS Address
SNTS
N/A
SNTS Latest News
Interactive Technical Analysis Chart Santarus, Inc. ( SNTS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Santarus, Inc.
SNTS Business Profile
Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company�s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company�s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.